JudithKarpMD

Oncology • Baltimore, MD

Professor of Oncology and Medicine, Director Leukemia Program, Johns Hopkins

Join to view full profile

Dr. Karp is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karp's full profile

Already have an account?

Office
600 N Wolfe St
Baltimore, MD 21287
Phone+1 410-955-8964

Education & Training

Johns Hopkins UniversityResidency, Internal Medicine, 1972 - 1974
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1971 - 1972
Stanford University School of MedicineClass of 1971

Certifications & Licensure

MD State Medical License 1975 - 2016

Clinical Trials

R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia Start of enrollment: 1999 Jun 01
Completed
Phase 1
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 1
MS-275 in Treating Patients With Hematologic Cancer Start of enrollment: 2001 Feb 01
Completed
Phase 1
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers Start of enrollment: 2001 Apr 01
Completed
Phase 2
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia Start of enrollment: 2001 Feb 01
Completed
Phase 1, Phase 2
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2001 Oct 01
Completed
Phase 2
A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) Start of enrollment: 2002 Jun 01
Completed
Phase 2
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2004 Jan 01
Completed
Phase 1
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2005 Mar 01
Completed
Phase 1
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders Start of enrollment: 2005 Nov 01
Completed
Phase 1
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia Start of enrollment: 2007 Apr 01
Completed
Phase 1
Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly Diagnosed Acute Myelogenous Leukemia (AML) Start of enrollment: 2011 May 01
Join now to see all

Publications & Presentations

PubMed

Genomic testing and patient rights.
C Michael Jones, Judith Karp, Dena S Davis
Journal of the National Cancer Institute. 2024-05-08
4 citations
Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia.
Stephanie Franco, Xue Geng, Valeriy Korostyshevskiy, Judith E Karp, Catherine Lai
Cancer. 2023-10-01
2 citations
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
Michael J Hochman, Megan Othus, Robert P Hasserjian, Alex Ambinder, Andrew Brunner
Leukemia. 2023-09-01

Journal Articles

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...
Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research

Authored Content

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018

Press Mentions

Improving Transparency in Phase 1 Clinical TrialsFebruary 9th, 2023
Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022
Judith Esther Karp, MD, Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who's WhoDecember 13th, 2017